Is there something like bio-dynamic breeding?

In this paper the differentiation made within the concept of naturalness will be used to explain the different approaches in breeding within the organic movement. The differentiation of the concept will result into a framework, which will be used as a tool to describe and explain the elements of bio-dynamic animal breeding. Bio-dynamics is a practical result out of the anthroposophical worldview. Bio-dynamics developed its own way to judge about relationships in the physical world, used its own language to express the holistic approach in agriculture and focused on additional relationships within the world

Effects of homeopathic and antibiotic mastitis treatment considering mediumterm parameters in an organic dairy herd

Introduction: Homeopathic treatment is a common method against bovine mastitis in organic herds. In a study conducted in a large biodyn farm in Brandenburg (D) considering 261 cases of acute or chronical mastitis, we used four different combinations of homeopathic remedies depending on clinical state of the mastitis (e.g. general findings, pain, swelling or secretion). The remedies were administrated orally. The control group was treated with antibiotics intracisternally for three days at minimum until the cow was clinically cured or defined as therapy failure. While the cure rate was calculated from clinical and laboratory data (bacterial findings and somatic cell count), the further development of the treated cows during the lactation was confirmed using monthly provided somatic cell counts of cows, mastitis and culling data. Results: We found an overall cure rate (complete healing) after administration of homeopathic remedies (H) of 21.7 % compared to 35.8 % in the antibiotically treated control group (A). Though there was an obviously poor treatment success in the homeopathy group, we found no remarkable depression of general udder health in the herd. So it was fair to assume that there must exist positive mediumterm effects of homeopathic remedies. We compared the parameters "Remain in Lactation (RIL)", "Acceptable Cell Count (ACC; < 200.000/ ml)" and analysed the reasons of culling or leaving production by other reasons. We found that there were no differences in RIL (H: 26 % vs. A: 24 %) and ACC (14 % vs. 10 %) in general six month after treatment. The risk of unsuccessful homeopathic treatment during the observing time only was higher in cases of Staph. aureus mastitis and in cows in second lactation. The most important fact was that treated cows which were classified as- subclinical infected 3 weeks after treatment- (n = 35) showed the best relative mediumterm results in the homeopathatic treatment group (ACC: 10 % vs. 0 %; RIL: 29 % vs. 7 %). We conclude that maybe the time frame of 3 weeks after treatment is not suitable to describe the effects of regulatory (homeopathic) mastitis treatment. The mediumterm effects at least six months after treatment are comparable to those after antibiotic administration. We suppose that it is possible to keep the udder health standard in a herd avoiding antibiotics

Are homeopathics able to replace antibiotics in the therapy of bovine mastitis? A placebo controlled randomized double-blind trial

To evaluate the effects of homeopathics on clinical mastitis cows and herd udder health this investigation was conducted in a Brandenburg bio-dyn herd of about 300 cows in two phases using a randomized doubleblind control trial design. After the first part in July 2002 the results preliminarily were evaluated and then the whole concept due to unsatisfying results was adapted. In Phase 1 a number of 121 clinical mastitis cases with 137 affected quarters matched the including criteria, in Phase 2 the number was 126 cows with 148 quarters. These animals were allocated to a code number which classified the case to Verum (n=65 and n=60) or placebo group (n=56 and n=66). In case of clinical mastitis cows were treated either by the oral dilution contending the required combined homeopathics or placebo. Animals were treated twice a day for 5 to 14 days (Phase 2: 1 to 7 days) depending on development of disease. In case of therapy failure in Phase 1 all animals were treated by an not coded homeopathic preparation and in Phase 2 by antibiotics according to bacteriological findings. Milk samples (double samples) for bacteriological and cell count investigation were taken before treatment (M1), 4 to 5 weeks after treatment termination (M2) and 7 to 8 weeks after treatment termination (M3). To evaluate the herd situation additional samples were taken after calving and before dry off. Healing criteria on the cow level was the clinical cure without secondary therapy and release to production. On quarter level the cure was determined by bacterial findings (BCR) and additional by cytological findings. A quarter was determined as „completely cured“, if no bacteria were found AND the cell count was below 100.000/ml. To assess the reduction of antibiotics within the concept it was hypothetically assumed that the mastitis cows had an average milk yield of 20,5 kg per day, was treated under conventional conditions by antibiotics over 3 days with a mean withdrawal time of 5 days (organic conditions x2). Afterwards, these theoretical values were compared to the extrapolated antibiotics input within our concept. Results While there is no difference between the cows in phase 1, on quarter level the verum group showed a significant higher complete cure rate than placebo group in Phase 2. These results are balanced by additional antibiotics treatment in case of therapy failure in the placebo group. The complete cure rate in the verum group after 8 weeks was 32% compared to 13% in placebo group (p<0.05). The limited cure results in single cows did not lead to an udder health depression of the herd. During the study the mean of somatic cell count could decreased by 100.000 cells/ml while the milk yield increased slightly by 250 kg/cow to 6.500 kg/cow/year. The number of actual antibiotic treatments during observation time compared to the number of mastitis cases which would be treated by antibiotics under conventionel conditions showed a reduction by 75%. The extrapolated reduction of milk loss by withdrawal was 25.000kg and the reduction of contaminated milk during treatment time was 13.100 kg per year for the herd. Discussion and Conclusions The increasing cure rates in the second part of the study are influenced by the enhancement of environmental preconditions in combination with the simplified therapy scheme. The therapists seemed to be more familiar with the fixed combinations of homeopathics so that positive effects of the homeopathics can be seen in this phase. After additional antibiotic treatments in case of therapy failure in specific infections (i.e. streptococci and staph. aureus) the cure rates could be elevated to a satisfying level. This fact shows that the limited and controlled use of antibiotics in organic herds can be helpful in the mastitis control. Regardless the conceptual modification to an antibiotic emergency concept, the massive reduction of antibiotics in combination with an increase of herd udder health justifies the therapy protocol in the second phase of the study. Hypothetically, the self cure of the animals is higher than known. The interaction between farmer or therapist and the cow could be a crucial criterion for the positive development of disease. As a conclusion, the integrated system consisting of preventive herd measures and complementary therapy added by limited antibiotic therapy. The precondition for the success is the attendance to optimize environmental conditions. The therapy system should be transparent, simple and easy to use. However, it is necessary to reflect every single mastitis case as a special one

Homöopathie statt Antibiotika: Feldstudie liefert erste Resultate

Nach gut zwei Jahren konnte in Brodowin (Brandenburg) eine groß angelegte deutsch-schweizerische Feldstudie abgeschlossen werden. An einer Herde von 350 Milchkühen wollten die Tierklinik der FU Berlin und das FiBL testen, ob die Homöopathie in der Behandlung von Euterentzündungen eine taugliche Alternative zu den Antibiotika bieten kann. Die Wirksamkeit der in dieser Studie angewendeten Homöopathika kann unter den gegebenen Betriebsbedingungen in der Mastitistherapie als sehr wahrscheinlich angesehen werden. Es lassen sich im Vergleich zur Antibiose befriedigende bakteriologische Heilungsraten erzielen, die für die Lieferfähigkeit der Milch von vorrangigem Interesse sind. Die insgesamt unbefriedigenden vollständigen Heilerfolge lassen sich durch die Gabe eines homöopathischen Prophylaktikums vor dem Trockenstellen und zur Geburt verbessern, insbesondere bei antibiotischer Therapie. Auch die Kombination aus homöopathischer und antibiotischer Trockenstellprophylaxe führt zu weniger Mastitiden in der Folgelaktation. Dieses Ergebnis erscheint auf den ersten Blick aus Sicht der Biolandwirtschaft nicht befriedigend, bietet aber Anlass zur Diskussion. Offenbar ist die homöopathische Behandlung allein nicht immer in der Lage, eine latente Mastitis vollständig auszuheilen. Die Kombination mit der Antibiose führt möglicherweise zu einer gleichzeitigen exogenen und endogenen Beeinflussung der Euterschleimhaut. Somit scheint es notwendig zu sein, in weiteren Forschungsprojekten Alternativen zur exogenen Therapie (statt Antibiose) zu konzipieren

Safety and Efficacy of Mistletoe extract (Viscum album) Iscador(R) P in Equine Sarcoid

Equine Sarcoid (ES), a semi malignant skin tumour, is the most common neoplasia of horses (Marti et al.1993). There is no generally effective single treatment existing and the recurrence rate is high (Martens et al.2001). Furthermore as a treatment obstacle, Sarcoids tend to occur as multi-focal tumours or can be found in critical locations (peri-ocular) where success of surgical interventions is very limited (Carstanjen et al.1997). Due to encouraging results in human medicine and small animals practice after adjuvant cancer treatment by mistletoe extracts (Biegel et al.2007) the viscum therapy could hypothetically fill a therapy gap for equine tumour diseases as well. Hence, goal of this clinical trial was to evaluate the safety and efficacy of Viscum album pini (Iscador® P) as a primary therapy of Equine Sarcoid in the context of a prospective, randomized, controlled, double-blind study. Material and Methods: 53 horses with histologically confirmed diagnosis Equine Sarcoid were randomly assigned as Iscador (I; n=32) or Control group (C; n=21). There are 23 mares, 25 geldings and 5 stallions ranged in age from 3 to 17 years with an average of 7.2 years. The horses received scalating dosages of Iscador® P starting at 0.1mg up to 20 mg extract per 1 ml dose or physiological NaCl solution 3 times a week over 105 days sub-cutanously into the pectoral region. The number, localization and morphology of the ES were observed and documented over 12 months. As target variable the positive outcome rate (PO rate) was calculated representing the patients status at the end of the investigation. Results: In the Iscador Group 13 horses (41%) showed an improvement (at least 50% tumour remission). Of these cases a number of 9 patients showed complete cure (28%). In the Control Group only 3 cases (14%; all with complete cure) were classified as improved (p<0.05). Discussion & Conclusions: Iscador® P extract (viscum album pini) represents a safe and efficient therapy alternative in Equine Sarcoids, particularly in cases of multi-focal character. In tumours grown in problematic localizations a therapy attempt with viscum album extracts should be conducted to avoid the risk of damage the intact surrounding tissue, particularly in the eye area. Iscador® P shows significantly better outcomes (cure and improvement) compared to placebo control. Younger horses and horses with more than 2 tumours are responding with higher PO rates than older patients and horses with 1 to 2 ES. This fact could support the control of multiple sarcoids which can be excised only by immense surgery expense. Further investigations to understand factors of response and non-.response have to be conducted in the future. Additionally, due to the good tolerance by the patients and the acceptance of long-term protocol the practicability of Iscador ® P therapy can be assumed. Younger horses responded more often with a positive outcome (PO) than older (Fig. 2a) with PO rates of 57%, 40% and 13% for horses being less than 5 years, 5 to 9 years and more than 9 years, respectively compared to PO 25%, 10% and 0% in control. A significant better therapy course appeared in the Iscador group for horses with >2 ES (Fig. 2b): a number of 12 of 25 horses (48%) showed an improvement, 9 of these a complete remission (36%) including ES localized at the critical areas (head and around the eyes) compared to 6% in the control group. Iscador® P extract (viscum album pini) represents a safe and efficient therapy alternative in Equine Sarcoids, particularly in cases of multi-focal character. In tumours grown in problematic localizations a therapy attempt with viscum album extracts should be conducted to avoid the risk of damage the intact surrounding tissue, particularly in the eye area. Iscador® P shows significantly better outcomes (cure and improvement) compared to placebo control. Younger horses and horses with more than 2 tumours are responding with higher PO rates than older patients and horses with 1 to 2 ES. This fact could support the control of multiple sarcoids which can be excised only by immense surgery expense. Further investigations to understand factors of response and non-.response have to be conducted in the future. Additionally, due to the good tolerance by the patients and the acceptance of long-term protocol the practicability of Iscador ® P therapy can be assumed

Muscular myostatin gene expression and plasma concentrations are decreased in critically ill patients.

BACKGROUND The objective was to investigate the role of gene expression and plasma levels of the muscular protein myostatin in intensive care unit-acquired weakness (ICUAW). This was performed to evaluate a potential clinical and/or pathophysiological rationale of therapeutic myostatin inhibition. METHODS A retrospective analysis from pooled data of two prospective studies to assess the dynamics of myostatin plasma concentrations (day 4, 8 and 14) and myostatin gene (MSTN) expression levels in skeletal muscle (day 15) was performed. Associations of myostatin to clinical and electrophysiological outcomes, muscular metabolism and muscular atrophy pathways were investigated. RESULTS MSTN gene expression (median [IQR] fold change: 1.00 [0.68-1.54] vs. 0.26 [0.11-0.80]; p = 0.004) and myostatin plasma concentrations were significantly reduced in all critically ill patients when compared to healthy controls. In critically ill patients, myostatin plasma concentrations increased over time (median [IQR] fold change: day 4: 0.13 [0.08/0.21] vs. day 8: 0.23 [0.10/0.43] vs. day 14: 0.40 [0.26/0.61]; p < 0.001). Patients with ICUAW versus without ICUAW showed significantly lower MSTN gene expression levels (median [IQR] fold change: 0.17 [0.10/0.33] and 0.51 [0.20/0.86]; p = 0.047). Myostatin levels were directly correlated with muscle strength (correlation coefficient 0.339; p = 0.020) and insulin sensitivity index (correlation coefficient 0.357; p = 0.015). No association was observed between myostatin plasma concentrations as well as MSTN expression levels and levels of mobilization, electrophysiological variables, or markers of atrophy pathways. CONCLUSION Muscular gene expression and systemic protein levels of myostatin are downregulated during critical illness. The previously proposed therapeutic inhibition of myostatin does therefore not seem to have a pathophysiological rationale to improve muscle quality in critically ill patients. TRIAL REGISTRATION ISRCTN77569430 -13th of February 2008 and ISRCTN19392591 17th of February 2011

Genetic landscape of congenital insensitivity to pain and hereditary sensory and autonomic neuropathies

Lischka A, Eggermann K, Record CJ, et al. Genetic landscape of congenital insensitivity to pain and hereditary sensory and autonomic neuropathies. Brain. 2023;146(12):4880-4890.Congenital insensitivity to pain (CIP) and hereditary sensory and autonomic neuropathies (HSAN) are clinically and genetically heterogeneous disorders exclusively or predominantly affecting the sensory and autonomic neurons. Due to the rarity of the diseases and findings based mainly on single case reports or small case series, knowledge about these disorders is limited.Here, we describe the molecular workup of a large international cohort of CIP/HSAN patients including patients from normally under-represented countries. We identify 80 previously unreported pathogenic or likely pathogenic variants in a total of 73 families in the >20 known CIP/HSAN-associated genes. The data expand the spectrum of disease-relevant alterations in CIP/HSAN, including novel variants in previously rarely recognized entities such as ATL3-, FLVCR1- and NGF-associated neuropathies and previously under-recognized mutation types such as larger deletions. In silico predictions, heterologous expression studies, segregation analyses and metabolic tests helped to overcome limitations of current variant classification schemes that often fail to categorize a variant as disease-related or benign.The study sheds light on the genetic causes and disease-relevant changes within individual genes in CIP/HSAN. This is becoming increasingly important with emerging clinical trials investigating subtype or gene-specific treatment strategies

Use of biologics in allergic and type 2 inflammatory diseases in the current Covid 19 pandemic

Klimek L, Pfaar O, Worm M, et al. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie. Allergo Journal . 2020;29(4):14-27